Leukemia/Lymphoma Trials

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL)

Principal Investigator: Katherine Matthay, MD

 

ADVL1314: A Phase I Study of Eribulin Mesylate (E7389, Ind #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas

Principal Investigator: Katherine Matthay, MD

 

ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib
(NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

Principal Investigator: Michelle Hermiston, MD, PhD

 

DFCI #13-563: Phase I trial of the selective inhibitor of nuclear export, KPT-330, in relapsed childhood ALL and AML

Principal Investigator: Elliot Stieglitz, MD

 

TACL 2014-001: A Phase 1 Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosophamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Principal Investigator: Michelle Hermiston, MD, PhD